PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 77 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $18,483,775 | +435.3% | 1,108,140 | +250.1% | 0.05% | +350.0% |
Q4 2022 | $3,453,015 | -83.9% | 316,500 | -87.5% | 0.01% | -85.9% |
Q3 2022 | $21,395,000 | -35.5% | 2,537,993 | -39.4% | 0.08% | -39.3% |
Q2 2022 | $33,153,000 | -52.0% | 4,191,200 | +43.8% | 0.14% | -48.9% |
Q1 2022 | $69,030,000 | -16.6% | 2,915,100 | +20.5% | 0.27% | -17.0% |
Q4 2021 | $82,756,000 | +6.4% | 2,419,763 | -44.8% | 0.33% | -3.2% |
Q3 2021 | $77,743,000 | +50.0% | 4,387,300 | +279.8% | 0.34% | +46.4% |
Q2 2021 | $51,845,000 | +112.4% | 1,155,200 | +22.6% | 0.23% | +104.4% |
Q1 2021 | $24,406,000 | +120.1% | 942,300 | +71.3% | 0.11% | +111.1% |
Q4 2020 | $11,088,000 | +468.0% | 550,000 | +238.5% | 0.05% | +350.0% |
Q3 2019 | $1,952,000 | -21.8% | 162,500 | +35.4% | 0.01% | +9.1% |
Q4 2017 | $2,496,000 | – | 120,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |